Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 6/25/2026

1. MU
2. QCOM
3. SPY
4. ICLR
5. JPM

6. FUL
7. LAES
8. NNE
9. DRI
10. CNXU

Get Alerts PRLD Hot Sheet

Price: $4.37 +2.34%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13, 2022.

The prerecorded presentation will become available on Monday, January 10, 2022 at 7:00 am ET and can be accessed by visiting the “Investors” page under the “Events & Presentation” section of the Prelude website, where a replay of the presentation will be available for a limited time.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative, potential best-in-class molecules targeting critical cancer cell pathways involved in cancer pathogenesis. Prelude’s initial clinical candidates, PRT543 and PRT811, are potent, selective, oral PRMT5 inhibitors in Phase 1 development for the treatment of advanced solid tumors, primary and secondary CNS cancers and select myeloid malignancies. PRT1419, a potent and selective MCL1 inhibitor, is in Phase 1 development for patients with relapsed/refractory hematologic malignancies and solid tumors. PRT2527, a highly selective CDK9 inhibitor, is anticipated to begin Phase 1 clinical development by year-end as a monotherapy in patients with selected solid tumors. In addition, the Company’s pipeline includes PRT-SCA2, a SMARCA2 protein degrader, PRT-K4, a highly selective kinase inhibitor, and additional discovery stage programs.

Investor Contacts:Stacey JurchisonExecutive Director, Corporate Affairs[email protected]

Melissa ForstArgot Partners212.600.1902[email protected]

Media Contact:Paige DonnellyArgot Partners212.600.1902[email protected]